Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON9: Olaparib and Cediranib in Relapsed Ovarian Cancer
NCT03278717Phase 3Unknown
- Sponsor
- University College London
- Start
- Jun 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of cediranib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by University College London. Status: unknown.
02
Drugs
cediranib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03278717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03278717.